Market research
SZLS.TO StageZero Life Sciences Ltd
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.07
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- CA8525403017
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.07
About
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SZLS.TO discussion.
5 years, 5 months ago
StageZero Life Sciences Ltd is currently in a long term downtrend where the price is trading 45.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
StageZero Life Sciences Ltd's total revenue rose by 2829.8% to $1M since the same quarter in the previous year.
Its net income has dropped by 651.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 90.3% to $-40K since the same quarter in the previous year.
Based on the above factors, StageZero Life Sciences Ltd gets an overall score of 3/5.